• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对伴有慢性功能障碍的肾移植受者的连续移植活检标本进行浆细胞、C4d 沉积和供体特异性抗体的检测。

Detection of plasma cells, C4d deposits and donor-specific antibodies on sequential graft biopsies of renal transplant recipients with chronic dysfunction.

机构信息

Department of Pathology, PTB, 2 rue Angélique Ducoudray 21070 Dijon, France.

出版信息

Transpl Immunol. 2010 Feb;22(3-4):110-4. doi: 10.1016/j.trim.2009.11.001. Epub 2009 Nov 10.

DOI:10.1016/j.trim.2009.11.001
PMID:19900552
Abstract

BACKGROUND

In order to look for a relationship between humoral mechanisms of rejection and chronic allograft dysfunction, plasma cells, C4d deposits and donor-specific antibodies (DSA) were simultaneously sought on serial biopsies of kidney allograft recipients.

PATIENTS AND METHODS

Ten recipients with chronic dysfunction (G1) and 8 recipients with long-term normal graft function (G2) were included. Biopsies and serums were sampled at early graft dysfunction (T1), between 8months and 2years (T2) and after the third year following transplantation (T3).

RESULTS

In G1, plasma cells represented 12.3% (T1), 8.2% (T2) and 14.1% (T3) of mononuclear cells. The mean percentage of plasma cells was 11.6% in G1 versus 0.4% in G2 (p<0.05). A progressive rise in C4d deposits was seen in G1, from 25% at T1 to 80% at T3. Donor-specific antibodies were identified in at least one serum sample of 60% of the patients in G1 and 12.5% of the patients in G2 (p=0.012), whereas donor-specific antibodies were eluted from at least one biopsy of 50% of the patients in G1 and 12.5% of the patients in G2 (p=0.03). In G1, C4d deposits were significantly associated with plasma cells (p=0.0012) and anti-HLA Abs in serum samples and/or eluates (p=0.026).

CONCLUSION

This study shows that plasma cells, DSA and C4d are associated in renal transplants developing chronic rejection.

摘要

背景

为了寻找排斥反应的体液机制与慢性移植物功能障碍之间的关系,对肾移植受者的连续活检标本同时寻找浆细胞、C4d 沉积和供体特异性抗体(DSA)。

患者与方法

纳入 10 例慢性功能障碍(G1 组)和 8 例长期正常移植功能(G2 组)的受者。在早期移植物功能障碍(T1)、8 个月至 2 年(T2)和移植后第 3 年(T3)时采集活检标本和血清。

结果

在 G1 组中,浆细胞分别占单核细胞的 12.3%(T1)、8.2%(T2)和 14.1%(T3)。G1 组的平均浆细胞百分比为 11.6%,而 G2 组为 0.4%(p<0.05)。G1 组的 C4d 沉积呈进行性升高,从 T1 时的 25%增加到 T3 时的 80%。在 G1 组的至少 60%的患者和 G2 组的 12.5%的患者的至少一个血清样本中鉴定出 DSA,而在 G1 组的至少 50%的患者和 G2 组的 12.5%的患者的至少一个活检标本中洗脱了 DSA(p=0.012)。在 G1 组中,C4d 沉积与浆细胞(p=0.0012)和血清样本和/或洗脱液中的抗 HLA Abs 显著相关(p=0.026)。

结论

本研究表明,在发生慢性排斥反应的肾移植中,浆细胞、DSA 和 C4d 相关。

相似文献

1
Detection of plasma cells, C4d deposits and donor-specific antibodies on sequential graft biopsies of renal transplant recipients with chronic dysfunction.对伴有慢性功能障碍的肾移植受者的连续移植活检标本进行浆细胞、C4d 沉积和供体特异性抗体的检测。
Transpl Immunol. 2010 Feb;22(3-4):110-4. doi: 10.1016/j.trim.2009.11.001. Epub 2009 Nov 10.
2
Anti-glutathione S-transferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients.C4d阳性肾移植受者中抗谷胱甘肽S-转移酶T1抗体介导的排斥反应。
Nephrol Dial Transplant. 2008 Jul;23(7):2393-8. doi: 10.1093/ndt/gfm955. Epub 2008 Feb 28.
3
Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies.同种异体移植排斥反应患者中针对HLA、MICA和GSTT1的供体特异性抗体以及肾活检中的C4d沉积。
Transplantation. 2009 Jan 15;87(1):94-9. doi: 10.1097/TP.0b013e31818bd790.
4
Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation.肾移植术后长期抗人白细胞抗原及供者特异性抗体的发生率与意义
Transpl Int. 2005 May;18(5):532-40. doi: 10.1111/j.1432-2277.2005.00085.x.
5
Peritubular capillary C4d staining in late acute renal allograft rejection--is it relevant?晚期急性肾移植排斥反应中肾小管周围毛细血管C4d染色——有相关性吗?
Clin Transplant. 2008 Jan-Feb;22(1):61-7. doi: 10.1111/j.1399-0012.2007.00745.x.
6
Vascular deposition of complement C4d is increased in liver allografts with chronic rejection.血管中补体 C4d 的沉积在发生慢性排斥反应的肝移植中增加。
Transpl Immunol. 2009 Sep;21(4):244-6. doi: 10.1016/j.trim.2009.06.004. Epub 2009 Jun 21.
7
Diagnostic value of C4d in renal allograft biopsies in different clinical settings: absence of C4d in grafts from non-heart-beating donors.C4d在不同临床情况下肾移植活检中的诊断价值:非心脏跳动供体肾移植中C4d的缺失
Transplant Proc. 2005 Nov;37(9):3688-9. doi: 10.1016/j.transproceed.2005.09.110.
8
Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients.肾移植受者中预先形成的C4d结合型和非C4d结合型HLA单抗原反应性的临床相关性
Transpl Int. 2009 Oct;22(10):982-9. doi: 10.1111/j.1432-2277.2009.00912.x. Epub 2009 Jul 10.
9
Clinical significance of C4d deposition in stable renal allografts in the early post-transplantation period.移植后早期稳定的肾移植中 C4d 沉积的临床意义。
Clin Transplant. 2009 Nov-Dec;23(6):812-8. doi: 10.1111/j.1399-0012.2008.00946.x. Epub 2008 Dec 19.
10
The role of C4d immunostaining in the evaluation of the causes of renal allograft dysfunction.C4d免疫染色在评估肾移植功能障碍原因中的作用。
Nephrol Dial Transplant. 2008 May;23(5):1735-41. doi: 10.1093/ndt/gfm843. Epub 2007 Dec 8.

引用本文的文献

1
The Role of Major Histocompatibility Complex in Organ Transplantation- Donor Specific Anti-Major Histocompatibility Complex Antibodies Analysis Goes to the Next Stage.主要组织相容性复合体在器官移植中的作用-供体特异性抗主要组织相容性复合体抗体分析进入下一阶段。
Int J Mol Sci. 2019 Sep 13;20(18):4544. doi: 10.3390/ijms20184544.
2
B Cell Immunity in Solid Organ Transplantation.实体器官移植中的B细胞免疫
Front Immunol. 2017 Jan 10;7:686. doi: 10.3389/fimmu.2016.00686. eCollection 2016.
3
Lymphoid Neogenesis and Tertiary Lymphoid Organs in Transplanted Organs.
移植器官中的淋巴新生与三级淋巴器官
Front Immunol. 2016 Dec 27;7:646. doi: 10.3389/fimmu.2016.00646. eCollection 2016.
4
Expanding the antibody-mediated component of plasma cell-rich acute rejection: A case series.扩大富含浆细胞的急性排斥反应中抗体介导的成分:病例系列
Indian J Nephrol. 2016 May-Jun;26(3):176-81. doi: 10.4103/0971-4065.159300.
5
The generation and maintenance of serum alloantibody.血清同种异体抗体的产生和维持。
Curr Opin Immunol. 2010 Oct;22(5):669-81. doi: 10.1016/j.coi.2010.08.018.